耐利奈唑胺或中介利奈唑胺、耐万古霉素的屎肠球菌菌株发病率的增加与利奈唑胺使用量的增加同步。
Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption.
作者信息
Scheetz Marc H, Knechtel Stephanie A, Malczynski Michael, Postelnick Michael J, Qi Chao
机构信息
Midwestern University Chicago College of Pharmacy, Infectious Diseases Pharmacist, Northwestern Memorial Hospital, 251 E. Huron St., Feinberg Pavilion LC-700, Chicago, IL 60611, USA.
出版信息
Antimicrob Agents Chemother. 2008 Jun;52(6):2256-9. doi: 10.1128/AAC.00070-08. Epub 2008 Apr 7.
Abstract
Clinical enterococcal resistance to linezolid is defined by the presence of the G2576T mutation. We evaluated the incidence of genetically proven linezolid resistance among vancomycin-resistant Enterococcus faecium strains and linezolid consumption for a possible association. A relationship was found (r(2) = 0.73, P = 0.03) and predicts increasing resistance with current trends of linezolid use.
摘要
临床肠球菌对利奈唑胺的耐药性由G2576T突变的存在来定义。我们评估了耐万古霉素屎肠球菌菌株中经基因证实的利奈唑胺耐药性的发生率以及利奈唑胺的使用量，以寻找可能的关联。结果发现了一种关系（r² = 0.73，P = 0.03），并预测随着利奈唑胺当前的使用趋势，耐药性会增加。
相似文献
1
Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption.
Antimicrob Agents Chemother. 2008 Jun;52(6):2256-9. doi: 10.1128/AAC.00070-08. Epub 2008 Apr 7.
2
Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment.
Eur J Clin Microbiol Infect Dis. 2006 Mar;25(3):197-8. doi: 10.1007/s10096-006-0100-8.
3
Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.
N Engl J Med. 2002 Mar 14;346(11):867-9. doi: 10.1056/NEJM200203143461121.
4
Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage.
J Clin Microbiol. 2006 Mar;44(3):1153-5. doi: 10.1128/JCM.44.3.1153-1155.2006.
5
Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
J Antimicrob Chemother. 2005 Oct;56(4):787-9. doi: 10.1093/jac/dki318. Epub 2005 Sep 5.
6
Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections.
Int J Antimicrob Agents. 2003 Jun;21(6):593-4. doi: 10.1016/s0924-8579(03)00090-6.
7
Spread of ampicillin/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals.
Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):815-25. doi: 10.1007/s10096-005-0056-0.
8
[Linezolid-resistant Enterococcus faecium: the first G2576T mutation in Turkey].
Mikrobiyol Bul. 2012 Jul;46(3):516-8.
9
Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
Antimicrob Agents Chemother. 2006 Dec;50(12):4217-9. doi: 10.1128/AAC.00518-06. Epub 2006 Sep 18.
10
Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2012 Aug;67(8):1819-23. doi: 10.1093/jac/dks146. Epub 2012 Apr 24.
引用本文的文献
1
Vancomycin-Resistant : Addressing Global and Clinical Challenges.
Antibiotics (Basel). 2025 May 19;14(5):522. doi: 10.3390/antibiotics14050522.
2
Duration of hospitalization increases the risk for long-term carriage of linezolid-resistant enterococci in critically ill patients.
Antimicrob Resist Infect Control. 2025 Apr 29;14(1):39. doi: 10.1186/s13756-025-01551-4.
3
Metabolic Rewiring of upon Drug Treatment and Antibiotics Resistance.
Metabolites. 2024 Jan 18;14(1):63. doi: 10.3390/metabo14010063.
4
Recent advances in the synthesis of new benzothiazole based anti-tubercular compounds.
RSC Adv. 2023 Jul 21;13(32):21890-21925. doi: 10.1039/d3ra03862a. eCollection 2023 Jul 19.
5
Treatment of Infective Endocarditis: A Continuing Challenge.
Antibiotics (Basel). 2023 Apr 4;12(4):704. doi: 10.3390/antibiotics12040704.
6
The Impact of an Antibiotic Stewardship Program on the Consumption of Specific Antimicrobials and Their Cost Burden: A Hospital-wide Intervention.
Risk Manag Healthc Policy. 2020 Sep 23;13:1701-1709. doi: 10.2147/RMHP.S265407. eCollection 2020.
7
Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Larval Infection Model.
Infect Drug Resist. 2019 Nov 12;12:3497-3505. doi: 10.2147/IDR.S219117. eCollection 2019.
8
Linezolid-resistant in leukemia patients: Rare cases with review of literature.
J Family Med Prim Care. 2019 Apr;8(4):1508-1510. doi: 10.4103/jfmpc.jfmpc_441_18.
9
Current Perspectives on Treatment of Gram-Positive Infections in India: What Is the Way Forward?
Interdiscip Perspect Infect Dis. 2019 Apr 7;2019:7601847. doi: 10.1155/2019/7601847. eCollection 2019.
10
Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.
F1000Res. 2018 Jan 2;7:3. doi: 10.12688/f1000research.11831.1. eCollection 2018.
本文引用的文献
1
Response to emerging infection leading to outbreak of linezolid-resistant enterococci.
Emerg Infect Dis. 2007 Jul;13(7):1024-30. doi: 10.3201/eid1307.070019.
2
Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci.
J Clin Microbiol. 2007 Sep;45(9):2917-22. doi: 10.1128/JCM.00913-07. Epub 2007 Jul 18.
3
Detection of mutations conferring resistance to linezolid in Enterococcus spp. by fluorescence in situ hybridization.
J Clin Microbiol. 2007 Oct;45(10):3421-3. doi: 10.1128/JCM.00179-07. Epub 2007 May 2.
4
The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
Diagn Microbiol Infect Dis. 2006 Dec;56(4):407-13. doi: 10.1016/j.diagmicrobio.2006.06.018. Epub 2006 Aug 23.
5
Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis.
J Clin Microbiol. 2006 Mar;44(3):1098-100. doi: 10.1128/JCM.44.3.1098-1100.2006.
6
Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Antimicrob Agents Chemother. 2004 Sep;48(9):3583-5. doi: 10.1128/AAC.48.9.3583-3585.2004.
7
Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs.
Diagn Microbiol Infect Dis. 2003 Nov;47(3):511-3. doi: 10.1016/s0732-8893(03)00153-6.
8
Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.
Antimicrob Agents Chemother. 2003 Oct;47(10):3318-20. doi: 10.1128/AAC.47.10.3318-3320.2003.
9
Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.
Clin Infect Dis. 2002 Nov 15;35(10):1269-72. doi: 10.1086/344177. Epub 2002 Oct 28.
10
Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.
Antimicrob Agents Chemother. 2002 Oct;46(10):3334-6. doi: 10.1128/AAC.46.10.3334-3336.2002.
Zotero 插件